Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF

Brain natriuretic peptide as a diagnostic marker for heart failure in hyperthyroid patients with ischemic heart disease

The Egyptian Journal of Internal Medicine volume 30, pages 63–67 (2018)Cite this article

Abstract

Objective

The aim of the study was to evaluate the value of the N-terminal prohormone of brain natriuretic peptide (NT-proBNP) as an early diagnostic marker for chronic heart failure (CHF) in hypothyroid patients with ischemic heart disease (IHD).

Materials and methods

A total of 120 patients with an age range between 42 and 64 years participated in the study. All patients were classified into four groups: the master first group includes 30 patients with IHD, CHF functional class II–III and hyperthyroidism; the second group includes 30 patients with IHD and CHF functional class II–III, but with normal thyroid function; the third group includes 30 hyperthyroid patients without CHF or IHD; and the fourth group includes 30 hyperthyroid patients with IHD, without CHF. All patients were subjected to the following: full clinical and functional assessment, measurement of NT-proBNP, echocardiography, and the 6-min walk test.

Results

NT-proBNP levels were high in all studied groups. NT-proBNP levels showed no significant difference between patients of second and fourth group. The master first group had the highest significant NT-proBNP concentrations than other studied groups. Thyroid hyperfunction in patients with IHD appears to stimulate the natriuretic peptides secretion at a level exceeding what is recommended for the initial diagnosis of CHF.

Conclusion

The highest NT-proBNP level in hyperthyroid patients with IHD apparently is caused by stimulation of natriuretic peptide secretion by both thyroid hyperfunction and myocardial ischemic changes, which determine the need to check out the cut-off value of NT-proBNP level as a serological marker for the initial diagnosis of heart failure of such patients’ category.

References

  1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013; 380:2163–2196.

    Article  Google Scholar 

  2. Roger VL. Epidemiology of heart failure. Circ Res 2013; 113: 646–659.

    Article  CAS  Google Scholar 

  3. Stewart S, Wilkinson D, Hansen C, Vaghela V, Mvungi R, McMurray J, et al. Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. Circulation 2008; 118:2360–2367.

    Article  Google Scholar 

  4. Bloomfield GS, Barasa FA, Doll JA, Velazquez EJ. Heart failure in sub-Saharan Africa. Curr Cardiol Rev 2013; 9:157–173.

    Article  Google Scholar 

  5. Kenchaiah S, Narula J, Vasan RS. Risk factors for heart failure. Med Clin North Am 2004; 88:1145–1172.

    Article  Google Scholar 

  6. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol 2008; 101:1016–1022.

    Article  Google Scholar 

  7. Van den Akker M, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998; 51:367–375.

    Article  Google Scholar 

  8. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7:481–493.

    Article  CAS  Google Scholar 

  9. Sawin CT, Castelli WP, Hershman JM, McNamara P, Bacharach P. The aging thyroid. Thyroid deficiency in the Framingham study. Arch Intern Med 1985; 145:1386–1388.

    Article  CAS  Google Scholar 

  10. Nw S, Ew G. Serum thyrotropin, thyroxine, and thyroid antibodies in the United States population (1988 to 1994): NHANES III. J Clin Endocrinol Metab 2002; 87:489–499.

    Article  Google Scholar 

  11. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37:2129–2200.

    Article  Google Scholar 

  12. Farmakis D, Filippatos G, Tubaro M, Peacock WF, Disomma S, Mueller C, et al. Natriuretic peptides in acute coronary syndromes: prognostic value and clinical implications. Congest Heart Fail 2008; 14:25–29.

    Article  Google Scholar 

  13. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330:625.

    Article  CAS  Google Scholar 

  14. Wei T, Zeng C, Tian Y, Chen Q, Wang L. B-type natriuretic peptide in patients with clinical hyperthyroidism. J Endocrinol Invest 2005; 28:8–11.

    Article  CAS  Google Scholar 

  15. Schultz M, Faber J, Kistorp C, Jarlov A, Pedersen F, Wiinberg N, et al. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol (Oxf) 2004; 60:54–59.

    Article  CAS  Google Scholar 

  16. Hobbs F, Davis R, Roalfe A, Hare R, Davies M, Kenkre J. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 2002; 324:1498.

    Article  CAS  Google Scholar 

  17. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. Circulation 1998; 97:1921–1929.

    Article  CAS  Google Scholar 

  18. Talwar S, Squire I, Downie P, McCullough A, Campton M, Davies J, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction. Correlation with left ventricular systolic dysfunction. Eur Heart J 2000; 21:1514–1521.

    Article  CAS  Google Scholar 

  19. Campeau L. The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. Can J Cardiol 2002; 18:371–379.

    PubMed  Google Scholar 

  20. Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. Circulation 2014; 64:1929–1949.

    Google Scholar 

  21. Council ES, Redon J, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34:2159–2219.

    Article  Google Scholar 

  22. The criteria committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. Boston, MA: The criteria committee of the New York Heart Association; 1994; 253–256.

    Google Scholar 

  23. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132: 919–923.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Sung MM, Dyck JR. Age-related cardiovascular disease and the beneficial effects of calorie restriction. Heart Fail Rev 2012; 17:707–719.

    Article  Google Scholar 

  25. Eckel R, York D, Rössner S, Hubbard V, Caterson I St, Jeor S, et al. Obesity, a worldwide epidemic related to heart disease and stroke: executive summary: AHA conference proceedings prevention conference VII. Circulation 2004; 110:2968–2975.

    Article  Google Scholar 

  26. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968–977.

    Article  CAS  Google Scholar 

  27. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347:305–313.

    Article  Google Scholar 

  28. Wilson PW, D’agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162:1867–1872.

    Article  Google Scholar 

  29. Jonsson S, Hedblad B, Engstrom G, Nilsson P, Berglund G, Janzon L. Influence of obesity on cardiovascular risk. Twenty-three-year follow-up of 22,025 men from an urban Swedish population. Int J Obes Relat Metab Disord 2002; 26:1046–1053.

    Article  CAS  Google Scholar 

  30. McAllister RM, Delp MD, Laughlin MH. Thyroid status and exercise tolerance. Cardiovascular and metabolic considerations. Sports Med 1995; 20:189–198.

    Article  CAS  Google Scholar 

  31. Kahaly GJ, Kampmann C, Mohr-Kahaly S. Cardiovascular hemodynamics and exercise tolerance in thyroid disease. Thyroid 2002; 12:473–481.

    Article  Google Scholar 

  32. Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol 2010; 6:431–443.

    Article  Google Scholar 

  33. Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of thyroid hormone on cardiac function – the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab 2002; 87:968–974.

    Article  CAS  Google Scholar 

  34. Leonard J. Hyperthyroidism as a high cardiac output state. Am Heart J 1970; 79:265–275.

    Article  Google Scholar 

  35. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation 1993; 87:1435–1441.

    Article  CAS  Google Scholar 

  36. Dörr M, Wolff B, Robinson DM, John U, Lüdemann J, Meng W, et al. The association of thyroid function with cardiac mass and left ventricular hypertrophy. J Clin Endocrinol Metab 2005; 90:673–677.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medicine, Zagazig University, 44519, Sharkyia Governorate, Zagazig City, Egypt

    Hazem M. El-Ashmawy (MD)

  2. Department of Cardiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Ekhlas M. Hussein

  3. Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Azza M. Ahmed

Authors
  1. Hazem M. El-Ashmawy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ekhlas M. Hussein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Azza M. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hazem M. El-Ashmawy.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El-Ashmawy, H.M., Hussein, E.M. & Ahmed, A.M. Brain natriuretic peptide as a diagnostic marker for heart failure in hyperthyroid patients with ischemic heart disease. Egypt J Intern Med 30, 63–67 (2018). https://doi.org/10.4103/ejim.ejim_81_17

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_81_17

Keywords